Why Nanoparticles Struggle to Reach Ovarian Cancer Cells

CU Anschutz researchers find that immune proteins can divert cancer-targeting nanoparticles away from ovarian tumors, pointing to a potential strategy for improving treatment delivery

Microscopic particles called nanoparticles hold promise for delivering cancer treatments directly to tumors, potentially making therapies more effective while sparing healthy cells. But a major obstacle stands in the way: Other cells in the body can intercept these tiny particles before they reach their intended targets.

New research published today in ACS Nano by scientists from the University of Colorado Anschutz and the University at Buffalo sheds light on why this happens and identifies a potential way to overcome this obstacle.

The researchers focused on ovarian cancer, which remains difficult to detect in its early stages. They investigated nanoparticles designed to recognize claudin-4 (CLDN4), a protein found on approximately 80% of the most common type of ovarian cancer. By attaching molecules that recognize this protein to nanoparticles, scientists have hoped to improve how the disease is detected and treated by guiding the particles directly to target cancer cells.

Their study found that while the nanoparticles successfully targeted ovarian cancer cells in laboratory experiments, they were far less selective in animal models. Instead, immune cells and other cells surrounding the tumors absorbed many of the particles, limiting their ability to reach the cancer cells.

"This is the first study that comprehensively explores targeting of CLDN4 in ovarian cancer using nanoparticles and specifically focuses on the immune barriers that determine the targeting efficiency," said the paper's senior author Dmitri Simberg, PhD, an associate professor at the CU Anschutz Skaggs School of Pharmacy and Pharmaceutical Sciences and co-director of the Colorado Center for Nanomedicine and Nanosafety.

How the complement system interferes with nanoparticle delivery

The findings point to the complement system, a part of the body's immune defenses, as a key contributor to this interference. The complement system normally helps protect the body by recognizing foreign substances and marking them for removal by immune cells. However, researchers found evidence that this same protective response can work against nanoparticles designed to target cancer. When complement proteins attach to nanoparticles, they can make the particles more likely to be absorbed by immune cells before reaching their intended targets.

In laboratory experiments, researchers discovered that removing functional complement dramatically reduced nanoparticle uptake by immune cells, allowing relatively more particles to associate with cancer cells.

The findings suggest that blocking certain parts of the complement system could help improve the accuracy of nanoparticle delivery. Because medications that inhibit the complement system are already clinically available, researchers believe this approach could offer a promising path toward more precise cancer imaging and targeted therapies, although further studies are needed.

"For years, researchers have focused on making nanoparticles better at recognizing cancer cells. But our findings suggest that may only be part of the solution. We also need to understand how the immune system responds to these particles and how we can prevent it from interfering with their delivery," Simberg adds.

This research was conducted by a Pharmaceutical Sciences graduate student David Angarita in the Simberg lab, in collaboration with faculty across the CU Anschutz campus, including Benjamin Bitler, PhD, and Kian Behbakht, MD, MBA, in the Department of Obstetrics and Gynecology, Natalie Serkova, PhD, in the Department of Radiology and John Janetzko, PhD, in the Department of Pharmacology and Department of Pharmaceutical Sciences.

Key points:

    • Researchers at CU Anschutz and the University at Buffalo studied nanoparticles designed to target ovarian cancer cells.
    • The nanoparticles successfully targeted cancer cells in laboratory experiments but were less selective in animal models.
    • The complement system, part of the body's immune defenses, appears to contribute to nanoparticle uptake by immune cells.
    • Removing functional complement reduced immune-cell uptake in laboratory experiments.
    • The findings could inform future strategies for more precise cancer imaging and drug delivery but additional studies are needed.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.